Eli Lilly’s retatrutide delivers breakthrough results in obesity & knee osteoarthritis trial
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
TeleRay partners with Radiobotics, adding Artificial Intelligence to their pre-existing integrated best-in-class medical image and patient information distribution platform
Subscribe To Our Newsletter & Stay Updated